Optibac Bowel calm 80
This OptiBac Probiotics formula For bowel calm contains pure Saccharomyces boulardii, a natural and safe probiotic yeast with extensive scientific research on its benefits in supporting bowel health.
S. boulardii has been internationally acclaimed as the number one probiotic for diarrhoea - to reduce discomfort and urgency and restore regular bowel movements.
For bowel calm extra strength S. boulardii is a natural probiotic food supplement and not a medicine. It is a completely natural probiotic food supplement offering support for bowel health and comfort.
The unique probiotic also supports the digestive health of those with conditions such as Candida overgrowth, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD).
Saccharomyces boulardii – an exceptional probiotic which is sold widely in the US, Scandinavia, Germany & France. S. boulardii has undergone extensive clinical research proving its ability to flush out pathogenic bacteria such as E. coli and Salmonella and its therapeutic benefits against diarrhoea.
OptiBac Probiotics guarantees 5 billion live micro-organisms per vegetarian capsule until the best before date.
OptiBac Probiotics For bowel calm can be given to adults and children (over 3 years) with the following recommendations:
- Take one to two capsules depending on severity of symptoms and up to six capsules daily or as professionally directed.
- For young children or any patient unable to swallow capsules, the content of the capsules can be mixed with a cold meal or beverage.
No refrigeration necessary.
Saccharomyces boulardii Unique28, hydroxypropyl methylcellulose, potato starch, magnesium stearate, silicon dioxide
It is not recommended to give probiotics to severely immunosuppressed patients, infants with short bowel syndrome (SBS), post cardiac surgery patients, patients with pancreatitis, patients in the Intensive Care Unit (ICU) or patients with blood in the stool unless under a doctors care.
Saccharomyces boulardii - Scientific Research
Saccharomyces boulardii contains 5 billion live microorganisms of pure Saccharomyces boulardii probiotic guaranteed per capsule.
Clinical Research on Saccharomyces boulardii and diarrhoea
McFarland, L.V. & Bernasconi, P. (1993) Saccharomyces boulardii: A Review of an Innovative Biotherapeutic Agent. Microbial Ecology in Health and Disease; Vol. 6 pp. 157-171.
Hochter, W. et al (1990) Saccharomyces boulardii in acute adult diarrhea. Efficacy and tolerance of treatment. Munchener Medizinische Wochenschrift; Vol. 132 (12) pp. 188-192.
Cetina-Sauri, G. & Basto, S. (1994) Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Annales de Pediatrie; Vol. 41 (6) pp. 397-400.
Kurugol, Z. & Koturoglu, G. (2005) Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Paediatrica; Vol. 94 pp. 44-47.
Maupas, J.L. et al. (1983) Treatment of Irritable Bowel Syndrome (IBS) Double Blind Trial of Saccharomyces boulardii. Medecine Chirurgie Digestives. Vol. 12 (1) pp. 77 – 79.
Kotowska, M. et al. (2005)Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Alimentary Pharmacology & Therapeutics 21 (5), 583–590
Erdeve, O. et al. (2004) 'The probiotic effect of S.boulardii in a pediatric age group' Journal of Trop Pediatr. Aug;50(4) pp.234-6
D'Souza, A. et al. (2002) Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Care of the Elderly Section, Faculty of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London. BMJ 2002;324:1361 ( 8 June )
Kirchhelle, A. et al. (1996) Treatment of persistent diarrhoea with Saccharomyces boulardii in returning travellers. Results of a prospective study; Fortschr Med; Vol. 114 (11) pp. 136-140
Grandy, G. et al. (2010) Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children; BMC Infectious Diseases, Vol. 10 pp. 253
Clinical Research on Saccharomyces boulardii and Candida
Ducluzeau, R. & Bensaada, M. (1982) Comparative effect of a single or continuous administration of Saccharomyces boulardii on the establishment of various strains of Candida in the digestive tract of gnotobiotic mice. Annales de microbiologie. (Inst. Pasteur). 133: pp: 491-501
Jawhara, S. & Poulain, D. (2007) Saccharomyces boulardii decreases inflammation and intestinal colonisation by Candida albicans in a mouse model of chemically-induced colitis. Medical Mycology, Vol. 45. Issue 8. pp 691 - 700.
Berg, R. et al. (1993) Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomcyes boulardii. J Infect Dis. 1993,Nov;168(5):1314-8.
Murzyn, et al. (2010) Capric Acid Secreted by S. boulardii Inhibits C. Albicans. August 2010, Plos One, Vol. 5. Issue 8.
Clinical Research on Saccharomyces boulardii and Clostridium difficile disease
McFarland, L.V. et al. (1994) A randomised placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. The Journal of the American Medical Association. Vol. 271. pp. 1913 - 1918
Surawicz, C.M. et al (2000) The Search for a Better Treatment for Recurrent Clostridium difficile Disease: Use of High-Dose Vancomycin Combined with Saccharomyces boulardii. Clinical Infectious Diseases. Vol. 31 pp. 1012 – 1017
Buts, J. et al. (1993) Saccharomyces boulardii for Clostridium difficile-Associated Enteropathies in Infants. Journal of Pediatric Gastroenterology and Nutrition. Vol. 16 pp. 419 – 425
Surawicz, C.M. et al. (1989) Treatment of Recurrent Clostridium difficile Colitis with Vancomycin and Saccharomyces boulardii. The American Journal of Gastroenterology. Vol. 85 (10)
Surawicz, C.M. (2003) Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Practice & Research Clinical Gastroenterology. Vol. 17 (5) pp. 775 – 783
Castagliuolo, I. et al. (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 67(I): 302 - 307.
Pothoulakis, C. et al. (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin: A binding and enterotoxicity in rat ileum. Gastroenterology: 104(4): 1108 - 1115.
Tung, J.M et al. (2010) Prevention of Clostridium difficile with Saccharomyces boulardii: A systematic review; Canadian Journal of Gastroenterology, Vol. 23(12) pp. 817-821
Clinical Research on Saccharomyces boulardii and Inflammatory Bowel Disease
Guslandi, M. et al. (2000) Saccharomyces boulardii in Maintenance Treatment of Crohn's Disease. Digestive Diseases & Sciences. Vol 45, 7, 1462 - 1464.
Guslandi, M. et al. (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology & Hepatology. Vol. 15 pp. 697 – 698.
We Also Recommend